Statement from the Board of Directors of Procaps Group
22 Dezember 2023 - 12:45AM
Business Wire
Procaps Group (NASDAQ: PROC) ("Procaps"). Having completed the
last ordinary meeting of 2023 on December 19th in which Ruben
Minski acted as CEO of the Procaps Group for the last time, and
taking into account that as of January 15th, 2024 he will take over
as Executive Chairman of the Board, which resulted from a planned
and communicated process to the market since February of this year,
we would like to express our appreciation to Ruben for his
inspiring and visionary leadership that has allowed Procaps to be a
leading organization in the pharmaceutical sector in the Region
today, recognized and valued in the market by the different
stakeholders.
Throughout his career in the Organization, Ruben has
demonstrated great experience and leadership in managing in a very
positive way the Company's growth, as well as navigating moments of
difficulty and uncertainty, imbuing the more than 5,000 employees
of the Procaps Group with a daring and resilient vision to
successfully face the challenges encountered.
In these more than four decades of management, the Organization
has achieved major milestones that reflect its position in the
international market, such as being the first pharmaceutical
company in Latin America to be certified for RX products by the FDA
in 2009 and becoming the first Latin American pharmaceutical
company to enter Nasdaq in 2021, thus strengthening its commitment
to continue generating growth with profitability.
Today, the Procaps Group has a direct presence in 13 countries
in the Americas, with production centers in Colombia, Brazil, El
Salvador and from 2022 in the United States, which has allowed it
to reach more than 50 territories through its different business
lines and products.
These are the result of the strategic vision with which the
Organization has been led, placing innovation at the center of the
business and its organizational culture, with a portfolio of 44
patents granted and 36 pending in different geographies.
Ruben has been a promoter of the organic and inorganic growth of
the Organization, which today has a pipeline of more than 100
products under development, more than 3,000 sanitary registrations
in force and close to 1,100 in evaluation process at the regulatory
entities of the different regions that have positioned the Company
as the one with the highest growth within the 10 organizations with
the highest market share in the Region and within the 3 most
prescribed by the medical body (*). Additionally, the Organization
has a systemic M&A program that permanently assesses the best
options to add significant value to the Company's shareholders, in
order to close profitable and synergic transactions.
Thus, under Ruben's vision of growth and leadership to date, it
has been the fundamental basis for Procaps to continue with its
long-term strategy, leaving the solid foundations of a company that
has successfully faced the external difficulties and dynamics that
surround it, leveraged by a corporate governance that promotes
transparency and strict compliance with regulations in the markets
where it operates.
We value the commitment of the entire management team that has
surrounded Ruben during these years and express our satisfaction
with the results obtained in the midst of an environment marked by
significant uncertainties, thus reinforcing our confidence in the
path that has been built.
As announced last November after completing a rigorous search
process for a new CEO, we welcome Jose Antonio Vieira, who will
join the Organization as of January 15, 2024.
We are convinced that Jose Antonio, with our full support, will
continue and strengthen the Company's strategic vision with a focus
to continue driving profitable and sustainable growth to ensure an
increasingly successful future, creating much more value for the
Organization and its investors.
* IQVa / Close Up Sep/2023
About Procaps Group
Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading
developer of pharmaceutical and nutraceutical solutions, medicines,
and hospital supplies that reach more than 50 countries in all five
continents. Procaps has a direct presence in 13 countries in the
Americas and more than 5,500 employees working under a sustainable
model. Procaps develops, manufactures, and markets over-the-counter
(OTC) pharmaceutical products and prescription pharmaceutical drugs
(Rx), nutritional supplements and high-potency clinical
solutions.
For more information, visit www.procapsgroup.com or Procaps’
investor relations website investor.procapsgroup.com
This press release includes “forward-looking statements.”
Forward-looking statements may be identified by the use of words
such as “forecast,” “intend,” “seek,” “target,” “anticipate,”
“believe,” “expect,” “estimate,” “plan,” “outlook,” and “project”
and other similar expressions that predict or indicate future
events or trends or that are not statements of historical matters.
Such forward-looking statements include projections on Mr. Vieira’s
expected future performance as well as the expected benefits to be
achieved by the appointment of Mr. Vieira as chief executive
officer, and there can be no assurance that any such projections or
benefits underlying the appointment of Mr. Vieira as chief
executive officer will be obtained. A number of factors could cause
actual results or outcomes to differ materially from those
indicated by such forward-looking statements. These forward-looking
statements involve a number of risks, uncertainties (some of which
are beyond our control), or other assumptions that may cause actual
results or performance to be materially different from those
expressed or implied by these forward-looking statements. These
risks and uncertainties include, but are not limited to, the risks
included under the header “Risk Factors” in Procaps’ annual report
on Form 20-F filed with the SEC, as well as Procaps’ other filings
with the SEC. Should one or more of these risks or uncertainties
materialize, or should any of our assumptions prove incorrect,
actual results may vary in material respects from those projected
in these forward-looking statements. We undertake no obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities laws. Accordingly, you
should not put undue reliance on these statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231221418385/en/
Investor Contact: Melissa Angelini IR Director - Procaps
Group ir@procapsgroup.com investor.procapsgroup.com
Procaps (NASDAQ:PROC)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Procaps (NASDAQ:PROC)
Historical Stock Chart
Von Dez 2023 bis Dez 2024